| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 6/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
OCPH Overview
October Pharma S.A.E manufactures and sells pharmaceutical products.
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م110.00 |
| 52 Week High | ج.م90.00 |
| 52 Week Low | ج.م132.00 |
| Beta | 1.45 |
| 1 Month Change | 0% |
| 3 Month Change | 15.74% |
| 1 Year Change | 10.00% |
| 3 Year Change | 83.36% |
| 5 Year Change | n/a |
| Change since IPO | 1,057.89% |
Recent News & Updates
Shareholder Returns
| OCPH | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0% | -2.1% | 1.3% |
| 1Y | 10.0% | 1.9% | 10.0% |
Return vs Industry: OCPH exceeded the EG Pharmaceuticals industry which returned 1.8% over the past year.
Return vs Market: OCPH exceeded the EG Market which returned 8.2% over the past year.
Price Volatility
| OCPH volatility | |
|---|---|
| OCPH Beta | 1.45 |
| Industry Beta | 0.86 |
| Market Beta | 1 |
Stable Share Price: OCPH is less volatile than 75% of EG stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: OCPH's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | n/a | n/a | https://www.octoberpharma.com |
October Pharma S.A.E manufactures and sells pharmaceutical products. The company offers cardiovascular, CNS, cold and chest, dermatology, diabetology, gastroenterology, hepatology, NSAID’s, and urology medicines, as well as antibiotics and multivitamins. It provides its products in solid forms, such as tablets, capsules, and powders; liquid forms comprising syrups, drops, solutions, and sprays; creams and suppositories; soft gelatin capsules; and ampoules and vials.
October PharmaE Fundamentals Summary
| OCPH fundamental statistics | |
|---|---|
| Market Cap | ج.م660.00m |
| Earnings (TTM) | ج.م130.84m |
| Revenue (TTM) | ج.م619.23m |
5.0x
P/E Ratio1.1x
P/S RatioIs OCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OCPH income statement (TTM) | |
|---|---|
| Revenue | ج.م619.23m |
| Cost of Revenue | ج.م318.96m |
| Gross Profit | ج.م300.26m |
| Expenses | ج.م169.42m |
| Earnings | ج.م130.84m |
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
n/a
| Earnings per share (EPS) | 21.81 |
| Gross Margin | 48.49% |
| Net Profit Margin | 21.13% |
| Debt/Equity Ratio | 75.4% |
How did OCPH perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield14%
Payout RatioValuation
Is October PharmaE undervalued compared to its fair value and its price relative to the market?
>50%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: OCPH (EGP110) is trading below our estimate of fair value (EGP566.01)
Significantly Below Fair Value: OCPH is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: OCPH is good value based on its PE Ratio (5x) compared to the EG Pharmaceuticals industry average (5.5x).
PE vs Market: OCPH is good value based on its PE Ratio (5x) compared to the EG market (12.3x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate OCPH's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: OCPH is overvalued based on its PB Ratio (2.3x) compared to the EG Pharmaceuticals industry average (1.3x).
Future Growth
How is October PharmaE forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
14.7%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as October PharmaE has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has October PharmaE performed over the past 5 years?
29.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: OCPH has high quality earnings.
Growing Profit Margin: OCPH's current net profit margins (21.1%) are higher than last year (11.7%).
Past Earnings Growth Analysis
Earnings Trend: OCPH's earnings have grown significantly by 29% per year over the past 5 years.
Accelerating Growth: OCPH's earnings growth over the past year (112.2%) exceeds its 5-year average (29% per year).
Earnings vs Industry: OCPH earnings growth over the past year (112.2%) exceeded the Pharmaceuticals industry 10%.
Return on Equity
High ROE: OCPH's Return on Equity (45.2%) is considered outstanding.
Financial Health
How is October PharmaE's financial position?
Financial Position Analysis
Short Term Liabilities: OCPH's short term assets (EGP400.6M) exceed its short term liabilities (EGP279.1M).
Long Term Liabilities: OCPH's short term assets (EGP400.6M) exceed its long term liabilities (EGP43.7M).
Debt to Equity History and Analysis
Debt Level: OCPH's debt to equity ratio (75.4%) is considered high.
Reducing Debt: OCPH's debt to equity ratio has increased from 18.2% to 75.4% over the past 5 years.
Debt Coverage: OCPH's debt is well covered by operating cash flow (44.2%).
Interest Coverage: OCPH's interest payments on its debt are well covered by EBIT (7.2x coverage).
Balance Sheet
Dividend
What is October PharmaE current dividend yield, its reliability and sustainability?
2.73%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: OCPH's dividend (2.73%) is higher than the bottom 25% of dividend payers in the EG market (2.69%).
High Dividend: OCPH's dividend (2.73%) is low compared to the top 25% of dividend payers in the EG market (7.43%).
Stability and Growth of Payments
Stable Dividend: Whilst dividend payments have been stable, OCPH has been paying a dividend for less than 10 years.
Growing Dividend: OCPH has only been paying a dividend for 4 years, and since then payments have fallen.
Current Payout to Shareholders
Dividend Coverage: With its low payout ratio (13.8%), OCPH's dividend payments are thoroughly covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average board tenure
CEO
October PharmaE has no CEO, or we have no data on them.
Board Members
Experienced Board: OCPH's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
October Pharma S.A.E's employee growth, exchange listings and data sources
Key Information
- Name: October Pharma S.A.E
- Ticker: OCPH
- Exchange: CASE
- Founded: 1987
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: ج.م660.000m
- Shares outstanding: 6.00m
- Website: https://www.octoberpharma.com
Location
- October Pharma S.A.E
- Piece #190
- Street #25
- Cairo
- Egypt
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/10/17 14:31 |
| End of Day Share Price | 2021/10/14 00:00 |
| Earnings | 2021/06/30 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.